Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    plx7486
Show Display Options
Rank Status Study
1 Recruiting Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors
Conditions: Solid Tumors;   Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion Mutations;   Tenosynovial Giant Cell Tumor
Intervention: Drug: PLX7486 TsOH

Indicates status has not been verified in more than two years